The COVID-19 pandemic accelerated a change across the global healthcare ecosystem that has led to the rapid adoption of technology. Investors’ confidence in the sector is evidenced by…
According to the Deloitte 2021 Global Healthcare Outlook, the industry’s GDP share should average 10.3% in 2021 and 2022. An aging population, rapid clinical and technology advances, and continued healthcare spending should drive the industry’s growth. Consequently, the global healthcare and pharma market is expected to reach $1.58 trillion by 2027, registering a 4% CAGR.
VTRS is a global health care company that manufactures and delivers medicines, biosimilars and generics, and over-the-counter products. In addition, the Canonsburg, Pa.-based company provides therapeutic medicines for both non-communicable and infectious diseases. VTRS operates through segments that include Cardiovascular; Infectious diseases; Oncology; Immunology; CNS and anesthesia; Women’s healthcare; Diabetes and metabolism; Gastroenterology; Respiratory and allergy, and Dermatology.
In July, VTRS and Biocon Biologics Ltd. announced that the U.S food and Drug Administration (FDA) had approved “Semglee” as the first interchangeable biosimilar product under the 351(k) regulatory pathway. This will help the company expand the reach of important diabetes medicine to patients, physicians, payers, and providers.
For its the second quarter, ended June 30, 2021, VTRS’ net sales increased 69.2% year-over-year to $4.56 billion. The company’s free cash flow grew 40% from its year-ago value to $470.1 million. Its gross profit rose to 29.4% from the prior-year quarter to $1.33 billion. Also, the company’s EBITDA increased 125.2% year-over-year to $1.28 billion.
VTRS’ revenue is expected to increase 49.2% year-over-year to $17.82 billion in its fiscal year 2021. The company has an impressive earnings surprise history; it beat consensus EPS estimates in three of the trailing four quarters. Its EPS is estimated to grow 4.1% next year.
Of the four Wall Street analysts that have provided ratings for the stock, three rated it Buy. The $21.25 consensus price target represents a 54% potential gain from the $13.80 last closing price.
Headquartered in Shanghai, China, ZLAB is a commercial-stage biopharmaceutical and research-based company. It develops, manufactures, and commercializes transformative medicines for cancer, autoimmune and infectious diseases. ZLAB’s products include…
Continue reading at STOCKNEWS.com